1.Research progress on the anti-tumor differentiation effects of zoledronic acid in breast cancer
Zhenkun GU ; Yuanyuan REN ; Xiaolang DU ; Chen WANG
Tianjin Medical Journal 2016;44(9):1177-1180
Breast cancer is the highest incidence and mortality of malignant tumor in women. Recurrence and distant metastasis are the main cause of death. Zoledronic acid (ZOL) has the potential to inhibit bone resorption characteristics mediated by osteoclast, which not only could suppress tumor cell proliferation and start the apoptosis of tumor cells, but also might interfere the adhesion of cancer cells to bone matrices, thereby could inhibit the migration and invasion of tumor cells. In some preclinical studies zoledronic acid has been demonstrated to have the direct anti-tumor effects on breast cancer. There are different therapeutic effects in treatment with zoledronic acid between the premenopausal and post-menopausal patients with breast cancer. This review summarized basic and clinical research progress of the anti-tumor differentiation effect of zoledronic acid in breast cancer.
2.Preparation and Evaluation of Long-circulating Liposomes of Paraoxonase
Zhenkun HAN ; Jianbo SUN ; Dan LIU ; Haiyang HU ; Dawei CHEN ; Pengyi GU ; Min ZHAO
Journal of China Medical University 2010;(2):87-91
Objective To prepare the long-circulating liposomes of paraoxonase(PON).Methods The long-circulating liposomes of paraoxonase were prepared by film dispersion method.The encapsulation efficiency was determined by gel column.The effects of the factors on the encapsulation efficiency,such as the weight ratio of paraoxonase to phospholipid,cholesterol(Choi) to phospholipid,PEG-cholesterol (PEG-Chol) and the iron strength of water phase,were investigated respectively.Then the formulation was optimized by orthogonal design.Results The encapsulation efficiency of the paraoxonase liposomes was 87.66±3.46%,and the average diameter of the liposomes was about 126 nm.There was no significant change on encapsulation efficiency on 15 d at 4 ℃,and the activity of paraoxonase was maintained basically stable.Conclusion The preparation of PEG-modified paraoxonase liposomes was easy and practicable,and the property investigation in vitro showed that the paraoxonase liposomes were stable.
3.Early stage of antibody-mediated rejection after lung transplantation: A case report and literature review.
Zhenkun XIA ; Mingjiu CHEN ; Bei QING ; Wei WANG ; Linguo GU ; Yunchang YUAN
Journal of Central South University(Medical Sciences) 2021;46(10):1172-1176
Antibody-mediated rejection (AMR) is a rare and serious complication after lung transplantation, with no characteristic of pathological manifestation, no systematic standard treatment, and the poor efficacy and prognosis. We reported a case of early AMR after lung transplantation and the relevant literature has been reviewed. A male patient presented with symptoms of cold 99 days after transplantation and resolved after symptomatic treatment. He admitted to the hospital 14 days later because of a sudden dyspnea and fever. Anti-bacteria, anti-fungi, anti-virus, and anti-pneumocystis carinii treatment were ineffective, and a dose of 1 000 mg methylprednisolone did not work too. The patient's condition deteriorated rapidly and tracheal intubation was done to maintain breathing. Serum panel reactive antibody and donor specific antibody showed postive in humen leukocyte antigen (HLA) II antibody. Pathological examination after transbronchial transplantation lung biopsy showed acute rejection. Clinical AMR was diagnosed combined the donor-specific antibody with the pathological result. The patient was functionally recovered after combined treatment with thymoglobuline, rituximab, plasmapheresis, and immunoglobulin. No chronic lung allograft dysfunction was found after 3 years follow up. We should alert the occurrence of AMR in lung transplantation recipient who admitted to hospital with a sudden dyspnea and fever while showed no effect after common anti-infection and anti-rejection treatment. Transbronchial transplantation lung biopsy and the presence of serum donor-specific antibody are helpful to the diagnosis. The treatment should be preemptive and a comprehensive approach should be adopted.
Graft Rejection
;
Graft Survival
;
HLA Antigens
;
Humans
;
Isoantibodies
;
Lung Transplantation/adverse effects*
;
Male